János Banai

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Miguel Regueiro, Brian G. Feagan, Bin Zou et al. · Gastroenterology · 2016 · 320 citations · Full text

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

K Gecse, Barbara D. Lovász, Klaudia Farkas et al. · Journal of Crohn s and Colitis · 2015 · 182 citations · Full text

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

László Kiss, Tamás Szamosi, Tamás Molnár et al. · Alimentary Pharmacology & Therapeutics · 2011 · 159 citations · Full text

Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease

Péter L. Lakatos, Z Czeglédi, Tamás Szamosi et al. · World Journal of Gastroenterology · 2009 · 113 citations · Full text

Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohnʼs disease, while smoking decreases the risk of colectomy in ulcerative colitis

Tamás Szamosi, János Banai, Z Czeglédi et al. · European Journal of Gastroenterology & Hepatology · 2010 · 65 citations